Taken together, our studies demonstrate that the genetic ablation of YAP/TAZ or ATF4 or the pharmacologically blocking of their transcriptional target gene product SLC7A11 or the glutathione synthesis pathway can efficiently sensitize HCC tumors to Sorafenib therapy by unleashing ferroptosis to promote cell death. The gene discussed is SLC7A11; the disease is hepatocellular carcinoma.